Loading…
← CockpitCompetitor Analysis › 2206.HK Sichuan Neautus Traditional ChineseOpen in the cockpit ↗

Sichuan Neautus Traditional Chinese2206.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Major
Mkt cap
$779M
US dollars, full cap
$/day
$7.55M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 8.2%
Hurdle
n/a
no reverse DCF
Close · HKDHK$85.40
1D+4.5%
1W+23.8%
1Mn/a
3Mn/a
6Mn/a
YTDn/a
1Yn/a

What Sichuan Neautus Traditional Chinese does

No business profile yet.

Sichuan Neautus Traditional Chinese at a glance

Size Sichuan Neautus Traditional Chinese (2206.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $779M, the 641st largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$85.40 on 18 Nov 2026.

Growth Revenue grew 7.0% over the last twelve months (peer median +5.6%); the operating margin is 8.2% (peer median 12.0%).

Sichuan Neautus Traditional Chinese financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenuen/aHK$1.44BHK$1.35BHK$1.26BHK$903M
Revenue growth—+7%+7%+40%—
Gross profitn/aHK$263MHK$221MHK$224MHK$183M
EBITDAn/aHK$139MHK$122MHK$138MHK$111M
Net incomen/aHK$115MHK$96.6MHK$115MHK$90.0M
Free cash flown/aHK$91.2M-HK$17.5MHK$104MHK$5.68M
Capital expendituren/aHK$13.5MHK$24.5MHK$20.0MHK$21.1M
Total debtn/aHK$241MHK$173MHK$132MHK$178M

Quarterly statements and history in the cockpit →

Sichuan Neautus Traditional Chinese competitors and peer comparison

How Sichuan Neautus Traditional Chinese compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sichuan Neautus Traditional Chinese against its 20 peers (data as of 18 Nov 2026)
Measure2206.HKPeer medianRank in peer set
Revenue growth (TTM)+7.0%+5.6%10th highest of 19
Operating margin8.2%12.0%9th lowest of 19
Net debt / EBITDA0.3×-0.5×4th most indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Sichuan Neautus Traditional Chinese 2206.HKHong Kong$779Mn/a+7%8%n/an/an/a
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%6.7×33.9%+10.1%
Zhejiang Int'l 000411.SZChina$783M-21%+3%3%0.3×n/an/a
Ardelyx ARDXUnited States$784M-50%+18%-8%1.6×n/an/a
Jinghua Pharmaceutical 002349.SZChina$785M-8%+2%20%3.1×-2.5%+2.6%
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%0.9×-3.8%-0.8%
Bambusa Therapeutics BBTXUnited States$791Mn/an/an/an/an/an/a
Ironwood Pharmaceuticals IRWDUnited States$791M+22%+18%63%2.6×n/an/a
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%16.7×n/an/a
Knight Therapeutics GUD.TOCanada$792M+41%+36%6%1.8×6.6%+17.7%
Katakura Industries 3001.TJapan$765M+40%-2%15%2.4×0.3%+0.5%
Oric Pharmaceuticals ORICUnited States$795M-9%n/an/an/an/an/a
Sanofi India SANOFI.NSIndia$797M0%-6%26%4.1×16.3%-8.7%
Rigel Pharmaceuticals RIGLUnited States$801M+48%+2%26%2.5×1.5%+22.1%
Bide Pharmatech 688073.SSChina$801M+10%+10%19%3.1×13.9%+27.7%
Guizhou Bailing Group Pharmaceutical 002424.SZChina$755M-20%-25%2%2.5×13.5%-0.2%
Suven Life Sciences SUVEN.NSIndia$803M-1%+55%-4,452%789.4×n/an/a
Collegium Pharmaceutical COLLUnited States$806M-24%+8%15%2.3×-2.6%+20.3%
Chongqing Pharscin Pharmaceutical 002907.SZChina$752M-7%+8%10%5.3×9.4%-1.4%
CARsgen Therapeutics 2171.HKHong Kong$751M-45%+68%-170%28.6×n/an/a
Hygeia Healthcare 6078.HKHong Kong$811M-3%+2%14%1.8×4.6%+22.5%

Questions

Which companies are Sichuan Neautus Traditional Chinese's closest peers?
The cockpit's peer set: Bliss GVS Pharma (BLISSGVS.NS), Zhejiang Int'l (000411.SZ), Ardelyx (ARDX), Jinghua Pharmaceutical (002349.SZ), Guizhou Xinbang Pharmaceutical (002390.SZ), Bambusa Therapeutics (BBTX), Ironwood Pharmaceuticals (IRWD), Lexicon Pharmaceuticals (LXRX).

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.